Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...

As FDA shortages lift, patients and physicians explore new options for continued treatment with compounded GLP-1 medications.

Now that the shortage of semaglutide injection products has been resolved, the Food and Drug Administration (FDA) will restrict third parties ...

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

The offer may show employers how hard drug manufacturers will compete based on price, in at least some situations.

For Maria Rising, managing her health felt like chasing a phantom. The 30-year-old Lansing, Mich. consultant has for years ...

A rise in the use of non-FDA-approved diabetes and obesity medications has spurred health care professionals and medical ...

Wegovy contains the same main ingredient as Ozempic, semaglutide, and is FDA-approved for weight loss in people with obesity or who are overweight with at least one weight-related condition. It is ...

On February 21, 2025, the US Food and Drug Administration (FDA) revised its shortage categorization of semaglutide, a glucagon-like peptide 1 ...

Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now ...

Novo Nordisk is taking a page out of Eli Lilly’s playbook as the two GLP-1 drugmakers work to fend off compounding pharmacies ...

The U.S. Food and Drug Administration said on Monday it will not take action against compounding pharmacies making copies of ...